Search the Newsreel

Distribusi Voucher (DIVA) Mulai Alihkan Saham Buyback, Harga Saham Melejit

Earnings Flash (JAN) Janus Living Posts Q2 Adjusted FFO $0.24, vs. FactSet Est of $0.25

Earnings Flash (JAN) Janus Living, Inc. Reports Q2 Revenue $216.5M, vs. FactSet Est of $215.2M

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

Indivior Pharmaceuticals INDV has announced a definitive agreement to merge with Supernus Pharmaceuticals SUPN in a tax-free, all-stock merger of equals. The transaction will create a leading central nervous system (CNS)-focused biopharmaceutical company with a diversified portfolio of 11 marketed medicines spanning psychiatry, neurology …

Janus International Group (JBI) Expected to Release Quarterly Earnings on Tuesday

Janus International Group (JBI) is scheduled to release its Q2 2026 earnings before market open on Tuesday, August 11th. Analysts anticipate earnings of $0.13 per share and revenue around $238.8 million. The company's stock recently traded at $5.54, with institutional investors holding a significant …

Agenus Inc expected to post earnings of 5 cents a share - Earnings Preview

Agenus Inc is projected to report earnings of 5 cents per share. This information is presented as an earnings preview by Refinitiv, shared through TradingView News. The full article is available to subscribers of TradingView.

Supernus and Indivior merge to create scaled, CNS-focused entity

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form a diversified biopharmaceutical company focused on the central nervous system (CNS). The combined entity, which will operate under the name Supernus Inc. and trade on Nasdaq under 'SUPN', expects pro forma …

NuScale Power (SMR) Heads Into Earnings With Project Updates Putting Valuation Back In Focus

Here's What We Like About Venus Remedies' (NSE:VENUSREM) Upcoming Dividend

Supernus Pharmaceuticals (SUPN) Stock Rebounds As Revenue Growth Meets Profit Crunch

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)

Monteverde & Associates PC, a class action firm, has announced an investigation into Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) concerning its proposed sale to Indivior Pharmaceuticals, Inc. The firm is examining whether the deal, where Supernus shareholders would receive 1.5401 common shares of Indivior for …

Indivior and Supernus (SUPN) outline tax-free all-stock CNS merger of equals

Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. announced a definitive agreement to merge in an all-stock, tax-free transaction, creating a U.S. biopharmaceutical company focused on central nervous system (CNS) diseases. The combined entity will be headquartered in Rockville, Maryland, with Supernus CEO Jack A. …

Halper Sadeh LLC is Investigating Whether SUPN, ITGR, BOW are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We …

Supernus Pharmaceuticals Earnings: What To Look For From SUPN

Supernus Pharmaceuticals is set to report its Q2 earnings this Tuesday after market hours. Analysts expect the company's revenue to grow by 24.3% year-on-year, improving from the previous year's 5.6% increase. Despite Supernus Pharmaceuticals beating revenue expectations last quarter, it significantly missed EPS estimates, …

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus

Faruqi & Faruqi, LLP is investigating potential securities claims against Agenus Inc. on behalf of investors who suffered losses exceeding $50,000 between January 23, 2023, and July 17, 2024. The investigation stems from allegations that Agenus made false or misleading statements regarding the effectiveness …

Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form Supernus, Inc., a new CNS-focused pharmaceutical company. The combined entity will have a portfolio of 11 commercialized products across addiction, ADHD, depression, and Parkinson's disease, with nearly $2.2 billion in revenue. …

CNS-focused Supernus and Indivior agree merger terms

Supernus Pharma and Indivior have agreed to an all-stock merger, forming a new company, Supernus Inc., focused on CNS diseases with combined revenues of around $2.2 billion. The deal, expected to close in Q4, will see Indivior shareholders owning 56.5% of the new company …

Rockville's Supernus more than tripling size through merger of equals

Rockville's Supernus Pharmaceuticals is merging with Richmond-based Indivior in a "merger of equals" transaction. The combined company will be led by current Supernus CEO Jack Khattar and is expected to generate approximately $2.2 billion in annual revenue from nearly a dozen neurological and psychiatric …

Price to earnings forward of NuScale Power Corporation Class A – BX:SMR

This article provides financial information for NuScale Power Corporation Class A, traded under the symbol SMR on the BX Swiss exchange. It focuses on the company's price to earnings forward metric within the financial overview. The data and intellectual property are provided by various …

Supernus Q2 Falls To Loss, Despite 32% Revenue Jump; To Merge With Indivior In All-Stock Deal

(RTTNews) - Supernus Pharmaceuticals Inc. (SUPN) Monday reported a slip to loss in the second quarter, on one-time impairment charges, interest expense and a reversal of income tax benefit to an expense, despite a 32% increase in revenue, compared to the prior year. The …

Shareholder Alert: Ademi LLP investigates whether Supernus Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) for potential breaches of fiduciary duty related to its transaction with Indivior Pharmaceuticals. Supernus shareholders are set to receive 1.5401 common shares of Indivior for each Supernus share, resulting in Supernus stockholders owning approximately 43.5% …

Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics

Supernus Pharmaceuticals (SUPN) reported $219.06 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 32.4%. EPS of $0.54 for the same period compares to $0.91 a year ago. The reported revenue represents a surprise of +6.84% over the Zacks …

Here's How to Play NuScale Stock Before Q2 Earnings Release

NuScale Power Corporation SMR is slated to release second-quarter 2026 results on Aug. 5, after market close. The Zacks Consensus Estimate for revenues is pegged at $1 million, implying a decrease of 87.6% from the year-ago quarter. The consensus mark of -$0.13 per share …

Supernus jumps premarket on merger deal; GameStop drops

Investing.com - U.S. stock index futures advanced on Monday after President Donald Trump said negotiations with Iran were set to begin this week, easing geopolitical concerns that had rattled markets in recent weeks, while technology stocks attempted to extend their recovery following July's sharp …

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus

Faruqi & Faruqi, LLP is investigating potential claims against Agenus Inc. (NASDAQ: AGEN) and is reminding investors of the November 5, 2024, deadline to seek the role of lead plaintiff in a federal securities class action. The investigation follows a significant drop in Agenus's …

At a glance: stocks gapping up premarket

[Wall Street New York City] aluxum/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-up moves before the bell on Monday. Stock index futures were higher on Monday as investors looked forward to a busy week of corporate earnings …

Supernus Pharmaceuticals Reports 32% Second-Quarter 2026 Revenue Growth, Raises Full-Year Guidance and Announces Merger with Indivior

Supernus Announces Second Quarter 2026 Financial Results

Supernus Pharmaceuticals, Inc. Total revenues were $219.1 million in the second quarter 2026, a 32% increase compared to same period last year. Combined revenues of the Company's four growth products increased to $175.7 million in the second quarter 2026, representing an increase of 52% …

Supernus, Indivior merge to beef up brain drug portfolio

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Brain drug developers Supernus and Indivior on Monday announced plans to merge, bringing together two companies specializing in drugs for …

Supernus Pharmaceuticals Reports 32% Second-Quarter 2026 Revenue Growth, Raises Full-Year Guidance and Announces Merger with Indivior | SUPN Stock News

Supernus and Indivior Agree to All-Stock Merger of Equals

Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. announced a definitive agreement to merge in an all-stock, tax-free transaction, creating a U.S. biopharmaceutical company focused on central nervous system (CNS) diseases. The combined entity will be headquartered in Rockville, Maryland, with Supernus CEO Jack A. …

Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Earnings Results, Misses Estimates By $1.43 EPS

This article provides an overview of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), including its current stock price, historical performance, analyst forecasts, and financial data. It highlights key metrics such as market capitalization, earnings per share, revenue, and EBITDA, while also offering insights into the company's …

Why Supernus Pharmaceuticals Stock Topped the Market Today

Key Points The two companies will carry the Supernus name. Supernus also published its latest quarterly earnings release.10 stocks we like better than Supernus Pharmaceuticals › Supernus Pharmaceuticals (NASDAQ: SUPN) began the stock trading week on a high note, announcing a major merger alongside …

Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9%

Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9% Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 32.4% year on year to $219.1 million. The company's full-year revenue guidance of $875 …

ELSA Gelontorkan Rp100 Miliar, Buyback Saham Dimulai Hari Ini

NuScale Power (NYSE: SMR) Earnings Report Could Reverse A 50% Stock Decline

NuScale Power Corporation (SMR) has filed its quarterly earnings report (Form 10-Q) for the period ended June 30, 2026. The report details the financial condition and results of operations, highlighting a significant increase in outstanding Class A shares due to a completed at-the-market program …